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ABSTRACT 23 
The extensive genetic diversity of porcine reproductive and respiratory syndrome virus 24 
(PRRSV) strains is a major obstacle for vaccine development. We previously demonstrated 25 
that chimeric PRRSVs in which a single envelope gene (ORF3, ORF4, ORF5 or ORF6) was 26 
shuffled via DNA shuffling had an improved heterologous cross-neutralizing ability. In this 27 
study, we incorporate all of the individually-shuffled envelope genes together in different 28 
combinations into an infectious clone backbone of PRRSV MLV Fostera® PRRS. Five viable 29 
progeny chimeric viruses were rescued, and their growth characteristics were characterized in 30 
vitro. In a pilot pig study, two chimeric viruses (FV-SPDS-VR2,FV-SPDS-VR5) were found 31 
to induce cross-neutralizing antibodies against heterologous strains. A subsequent 32 
vaccination/challenge study in 72 pigs revealed that chimeric virus FV-SPDS-VR2 and 33 
parental virus conferred partial cross-protection when challenged with heterologous strains 34 
NADC20 or MN184B. The results have important implications for future development of an 35 
effective PRRSV vaccine that confers heterologous protection. 36 
 37 
Key words: Porcine reproductive and respiratory syndrome virus (PRRSV); envelope genes; 38 
DNA shuffling; vaccines; cross-protection; heterologous strains.  39 
 40 
41 
  
3 
 
Introduction 42 
RNA viruses have high mutation rates mainly due to the low fidelity of viral 43 
RNA-dependent RNA polymerases (Arnold et al., 2005; Vignuzzi et al., 2008). This rapid 44 
evolution due to high mutation rate usually leads to the generation of genetically and 45 
antigenically variable virus strains in the field, which can hinder the development of effective 46 
vaccines. Porcine reproductive and respiratory syndrome virus (PRRSV), the causative agent 47 
of one of the most economically important global swine diseases, PRRS, has an extremely 48 
high mutation rate (Lunney et al., 2010; Murtaugh et al., 2010; Snijder et al., 2013). 49 
Genetically diverse field strains of PRRSV have been constantly emerging over the past two 50 
decades since its initial isolation from pigs in 1989 (Murtaugh et al., 2010; Shi et al., 2010a). 51 
PRRSV is currently classified into two distinct genotypes, type 1 and type 2. Within type 2, it 52 
is further subdivided into at least 9 distinct genetic lineages (Shi et al., 2010a; Shi et al., 53 
2010b). It is estimated that the PRRSV mutation rate in the field is approximately 54 
10-2/site/year, which is higher than any of other known RNA viruses (10-3 to 10-5/site/year) 55 
(Hanada et al., 2005). The extensive heterogeneity of PRRSV presents challenges for the 56 
efficacy of current commercial vaccines, which are uniformly based on a single virus strain. 57 
Consequently the current vaccines generally confer only limited or partial cross-protection 58 
against heterologous PRRSV strains (Kimman et al., 2009; Li et al., 2014; Murtaugh and 59 
Genzow, 2011). 60 
PRRSV utilizes a discontinuous transcription strategy to synthesize a nested set of 61 
subgenomic mRNAs (sg mRNAs) which possess the same 5′-UTRs and 3′-UTRs as the 62 
genomic RNAs (Pasternak et al., 2006). Replicase ORF1a and ORF1ab, via ribosomal 63 
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frameshift-mediated translational reprogramming, generate nonstructural proteins (nsps) that 64 
direct viral genome replication and sg mRNA synthesis (Fang and Snijder, 2010). The 65 
structural protein-encoding region generates glycoprotein GP2 (encoded by ORF2a), the 66 
envelope proteins E (ORF2b), GP3 (ORF3), GP4 (ORF4), GP5 (ORF5), membrane protein 67 
M (ORF6), nucleocapsid protein N (ORF7) and recently identified small hydrophobic protein 68 
ORF5a (ORF5a) (Firth et al., 2011; Johnson et al., 2011; Snijder et al., 2013). These 69 
structural proteins are critically important to the viral life cycle and for inducing neutralizing 70 
antibodies. 71 
GP5, the major envelope glycoprotein, contains 3-4 N-linked glycosylation sites and 72 
neutralizing epitopes which may induce protective immunity (Ansari et al., 2006; Ostrowski 73 
et al., 2002; Wei et al., 2012a). In viral particles, GP5 and M proteins form heterodimers, 74 
which interact with cellular heparin sulfate contributing to virus entry into cells (Van 75 
Breedam et al., 2010). GP5 is also one of the most variable structural proteins showing only 76 
about 85% nucleotide sequence identity among type 2 PRRSV strains and about 62% identity 77 
between type 1 and type 2 PRRSV (Kappes et al., 2013; Music and Gagnon, 2010; Nelsen et 78 
al., 1999; Rowland et al., 1999). The GP5 has been extensively studied as a target for PRRSV 79 
vaccine development (Kimman et al., 2009; Murtaugh and Genzow, 2011). Minor envelope 80 
proteins (GP2, GP3, GP4 and E) form oligomeric complexes containing abundant N-linked 81 
glycosylation sites and have been shown to induce neutralizing antibodies (Costers et al., 82 
2010; Lee and Yoo, 2006; Wei et al., 2012b). Recent studies have shown that the minor 83 
envelope proteins play an important role in determining cell tropism by interacting with the 84 
cellular receptor CD163 (Das et al., 2010; Tian et al., 2012) Therefore, for the rational design 85 
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of an effective vaccine, both major and minor PRRSV envelope proteins should be 86 
considered. 87 
Molecular breeding through DNA shuffling accelerates gene evolution in vitro by 88 
mimicking the natural recombination process in vivo (Crameri et al., 1998; Stemmer, 1994). 89 
Compared to natural recombination, DNA shuffling rapidly generates recombinants with 90 
desired phenotypes in vitro (Dupuy et al., 2009; Patten et al., 1997). In the traditional DNA 91 
shuffling approach, a set of target gene fragments derived from parents are digested with 92 
DNase I to produce a pool of short DNA fragments, which are then reassembled through PCR 93 
amplification to generate a library of recombinants (Soong et al., 2000; Zhou et al., 2013). 94 
Recombinants with desired properties can then be screened from the library. The DNA 95 
shuffling approach has been successfully used to produce more stable and high-yield murine 96 
leukemia virus strains, and to broaden cross-neutralizing activities against dengue viruses 97 
(Apt et al., 2006; Powell et al., 2000). In our previous studies, by using molecular breeding 98 
through DNA shuffling, we have individually shuffled each of the GP3, GP4, GP5, and M 99 
genes of PRRSV (Ni et al., 2013; Zhou et al., 2013; Zhou et al., 2012). Numerous chimeric 100 
viruses were rescued and characterized. For example, chimeric virus DS722 (GP5 shuffled) 101 
showed an attenuated phenotype based on its pathogenicity (Ni et al., 2013). Chimeric viruses 102 
GP3TS22 (GP3 shuffled), GP4TS14 (GP4 shuffled), and MTS57 (M shuffled) displayed 103 
improved cross-neutralizing activities against heterologous virus strains in vitro (Zhou et al., 104 
2013; Zhou et al., 2012).  105 
In this present study, we hypothesize that integration of these single envelope 106 
gene-shuffled sequences together in different combinations into the genomic backbone of an 107 
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infectious clone based on a commercial PRRSV vaccine virus will generate novel chimeric 108 
viruses that confer cross-protection against heterologous virus challenges. Therefore, in this 109 
study we first generated a panel of chimeric viruses containing shuffled multiple envelope 110 
proteins in different combinations based on the genomic backbone of Fostera® PRRS, a 111 
commercial PRRSV vaccine virus. The shuffled chimeric viruses were successfully rescued 112 
and characterized for their growth characteristics in monkey kidney cell lines MARC-145 and 113 
ATCC CRL11171. An immunogenicity study in 21 pigs identified two chimeric viruses, 114 
FV-SPDS-VR2 and FV-SPDS-VR5, that both elicited significantly higher levels of 115 
cross-neutralizing antibodies compared to the parental virus. Importantly, in a 116 
vaccination/challenge study in 72 pigs, the chimeric virus FV-SPDS-VR2 and the parental 117 
virus were demonstrated to confer cross-protection when vaccinated pigs were challenged 118 
with heterologous strains NADC20 or MN184B.  119 
 120 
Results 121 
Rescue of chimeric viruses with shuffled multiple envelope genes 122 
In our previous studies, we have successfully generated four single envelope gene-shuffled 123 
chimeric PRRSV strains, in the genomic backbone of the virulent VR2385 PRRSV strain, in 124 
which the envelope genes (ORF3-6) were each individually shuffled. (Ni et al., 2013; Zhou et 125 
al., 2013; Zhou et al., 2012). Importantly, we demonstrated that these single envelope 126 
gene-shuffled chimeric viruses (GP3TS22, GP4TS14, and MTS57) induced higher levels of 127 
cross-neutralizing antibodies against heterologous virus strains than that of the backbone 128 
virus in vitro, or displayed an attenuated phenotype (DS722) while still inducing protection in 129 
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vivo. Both major and minor envelope proteins of PRRSV play important roles in inducing 130 
protective immune responses, in the present study we hypothesized that combining the 131 
shuffled chimeric sequences of the envelope genes from each of the four single-gene shuffled 132 
chimeric viruses into one single mosaic virus would induce maximal cross-protection against 133 
heterologous strains. To achieve this objective, we integrated the chimeric sequences of all 134 
shuffled envelope protein genes into a single PRRSV strain in the genomic backbone of the 135 
vaccine virus Fostera® PRRS (FV). Five full-length chimeric plasmid clones (FV-SPDS, 136 
FV-SPDS-FV5, FV-SPDS-FV25, FV-SPDS-VR2, and FV-SPDS-VR5) were constructed 137 
(Fig. 1), and the authenticity of these chimeric clones was verified by DNA sequencing of the 138 
final constructs.  139 
Following transfection of the full-length chimeric clones into BHK-21 cells, supernatants 140 
were harvested after two days (P0 virus) and used to inoculate fresh MARC-145 cells. At 3 to 141 
4 days post-inoculation, CPE was observed in inoculated MARC-145 cells, which were 142 
subsequently confirmed by IFA using PRRSV N-specific monoclonal antibody, indicative of 143 
the production of viable progeny virions and rescue of infectious chimeric viruses (Fig. 2A). 144 
To further confirm that the rescued progeny viruses originated from the respective transfected 145 
chimeric virus clones, the ORFs 2-6 were amplified from each of the P3 viruses by RT-PCR 146 
and sequenced. Sequence analyses revealed that the ORFs 2-6 of each rescued progeny virus 147 
contained the shuffled ORFs 2-6 gene sequences, as originally engineered at the level of the 148 
full-length virus clones. The results demonstrated the successful generation of viable 149 
chimeric virus progeny with multiple shuffled envelope genes. 150 
 151 
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Growth characteristics of the chimeric viruses containing multiple shuffled envelope genes in 152 
MARC-145 and ATCC CRL11171 cells 153 
In order to use these shuffled chimeric viruses as potential candidates for a modified 154 
live-attenuated vaccine (MLV), they must replicate well in cell cultures. Therefore, we 155 
investigated the growth characteristics of the multiple envelope gene-shuffled chimeric 156 
viruses in MARC-145 and ATCC CRL11171 cells. Using P3 viruses, MARC-145 cells were 157 
infected with the shuffled and parental viruses at an MOI of 0.1 to evaluate the growth 158 
kinetics. With the exception of chimera FV-SPDS-FV25, all other shuffled chimeric viruses 159 
displayed similar growth kinetics to the parental virus FV (Fig. 3A). The shuffled chimeric 160 
viruses FV-SPDS-FV5 and FV-SPDS-VR5 showed similar peak titers to parental virus FV 161 
(≈2.5×106TCID50/ml), while the FV-SPDS (≈4.0×105TCID50/ml) and FV-SPDS-VR2 162 
(≈6.3×105TCID50/ml) had slightly lower peak titers (<1 log10) compared to FV. The chimera 163 
FV-SPDS-VR2 showed an accelerated replication rate, reaching the peak virus titer earlier 164 
(≈12 h) than other viruses.  165 
To further characterize the growth kinetics of the shuffled chimeric viruses, we also tested 166 
virus replication in the cell line ATCC CRL11171, a monkey kidney cell line. Cells were 167 
inoculated with P0 chimeric viruses. CPE appeared from 3 to 4 days post-infection, and was 168 
verified by IFA using PRRSV-specific antibody (Fig. 2B). In growth kinetics, both shuffled 169 
chimeric and parental viruses (P3) replicated well in ATCC CRL11171 cells (Fig. 3B). There 170 
was no significant difference in peak infectious virus titers between MARC-145 and ATCC 171 
CRL11171 (Fig. 3C), although the time points at peak virus titers for most chimeric viruses 172 
in ATCC CRL11171 cells were about 12 h later compared to that in MARC-145 cells (Fig. 173 
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3A, 3B). Similarly, we observed that the chimera FV-SPDS-FV25 displayed an impaired 174 
growth whereas chimera FV-SPDS-VR2 had an accelerated growth rate. Collectively, the 175 
results showed that these multiple envelope gene-shuffled chimeric viruses replicated in both 176 
MARC-145 and ATCC CRL11171 cells to relatively high titers that are sufficient for use as a 177 
MLV. 178 
 179 
Two shuffled chimeric viruses, FV-SPDS-VR2 and FV-SPDS-VR5, induced cross-neutralizing 180 
antibodies against heterologous virus strains  181 
To screen for potential viable candidate vaccine strains, we conducted a small pilot animal 182 
study by experimentally infecting groups of 3 pigs with one of the five shuffled chimeric 183 
viruses or the parental virus to generate antisera specific to each virus. The six groups of pigs 184 
inoculated with shuffled viruses or parental virus seroconverted within 14 or 21 dpi and 185 
remained seropositive through the end of the study (Fig. 4), while the negative control pigs 186 
remained seronegative, indicating that all the five multiple envelope gene-shuffled viruses 187 
replicated in vivo and elicited immune responses in pigs. One pig in FV group had a very low 188 
S/P value compared to the other two pigs, and thus making the overall mean value of FV 189 
group lower than other groups. This was likely due to the individual difference caused by the 190 
small numbers of pigs (3) used in this pilot study.  191 
To assess whether the shuffled chimeric viruses can induce cross-neutralizing antibodies 192 
against heterologous PRRSV strains, an SVN assay was performed using serum samples 193 
collected at 49 dpi from pigs against parental virus FV as well as five heterologous PRRSV 194 
strains belonging to different genetic lineages (Zhou et al., 2013; Zhou et al., 2012). In the 195 
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SVN assay against the parental virus FV (Fig. 5A), the mean NA titers of the FV-SPDS-FV5 196 
(5.6) and FV-SPDS-FV25 (5.2) groups were slightly lower than that of the FV group (6.0), 197 
while the NA titers of the FV-SPDS, FV-SPDS-VR2, FV-SPDS-VR5 groups were much 198 
lower than that of the FV group, likely due to the fact that these three shuffled chimeric 199 
viruses contain less envelope protein sequences derived from FV.  200 
For the SVN against the heterologous strain VR2430 (Fig. 5B), most shuffled virus groups 201 
reached mean titers of about 4.0, but there was no significant difference compared to the FV 202 
group (4.1). However, the mean NA titer of the FV-SPDS-FV25 group (2.6) was significantly 203 
lower than that of the FV group (P=0.0018). For the SVN against PRRSV strain VR2385, a 204 
different sublineage of lineage 5 relative to strain VR2430 (Fig. 5C), the FV-SPDS-VR2 and 205 
FV-SPDS-VR5 groups had mean NA titers of 1.7 and 3.1, respectively, while the other 206 
groups displayed low (<1.0) or undetectable titers. For SVN against the heterologous strain 207 
NADC20 (Fig. 5D), the mean NA titers of the FV-SPDS group (2.0) and FV-SPDS-VR2 208 
group (4.0) were significantly higher than that of the FV group (0.8). For SVN against the 209 
heterologous strain MN184B (Fig. 5E), all groups had low (<1.0) or undetectable NA titers. 210 
For SVN against the heterologous strain FL12, most serum samples had undetectable NA 211 
titers (data not shown).  212 
The composite NA titers were generated by combining the individual NA titers against five 213 
respective heterologous strains (VR2430, VR2385, NADC20, MN184B, FL12), and analyzed 214 
to evaluate the cross-neutralizing ability for each of the five chimeric viruses (Fig. 5F). 215 
Chimeras FV-SPDS-VR2 (P=0.0115) and FV-SPDS-VR5 (P=0.0057) inoculated pigs 216 
displayed significantly higher NA titers against heterologous PRRSV strains compared to FV 217 
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inoculated pigs, although the two groups had relatively large error bars due to different titers 218 
against different heterologous strain. This suggested that two of shuffled viruses, 219 
FV-SPDS-VR2 and FV-SPDS-VR5, had an improved ability to induce cross-neutralizing 220 
antibodies in vitro against heterologous PRRSV strains. 221 
 222 
One shuffled chimeric virus, FV-SPDS-VR2, conferred cross-protection against challenge 223 
with heterologous PRRSV strains 224 
Since two of the shuffled chimeric viruses, FV-SPDS-VR2 and FV-SPDS-VR5, induced 225 
cross-neutralizing antibodies, these two chimeric viruses were subsequently selected for a 226 
vaccination/challenge efficacy study in pigs (Table 1). Two heterologous strains NADC20 227 
(lineage 9) and MN184B (lineage 1) were used as challenge viruses. When challenged with 228 
NADC20 or MN184B, 7 pigs in the non-vaccinated/NADC20 challenged group and 4 pigs in 229 
the non-vaccinated/MN184B challenged group developed high body temperatures (>104.5°F) 230 
(Fig. 6). However, only 1-2 pigs in the shuffled chimeric virus- or parental FV-vaccinated 231 
groups developed high temperatures when challenged with NADC20 (Fig. 6A). Only 2 pigs 232 
in the FV-SPDS-VR2-vaccinated group and 3 pigs in the FV-SPDS-VR5-vaccinated group 233 
developed fevers after challenge with MN184B, while 6 pigs displayed fevers in the 234 
FV-vaccinated/MN184B-challenged group (Fig. 6B).  235 
At necropsy, both FV- and FV-SPDS-VR2-vaccinated groups showed significantly 236 
decreased gross lung lesion scores compared to the non-vaccinated control group when 237 
challenged with either NADC20 or MN184B (Fig. 7A, 7B). For the NADC20 challenge, the 238 
FV-vaccinated group had a lower mean gross lung lesion score than the FV-SPDS-VR2- and 239 
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FV-SPDS-VR5-vaccinated groups (Fig. 7A). For the MN184B challenge, the 240 
FV-SPDS-VR2-vaccinated group had a numerically lower mean gross lung score than the 241 
FV-vaccinated group (FV-SPDS-VR2: 11; FV: 19), although the difference was not 242 
statistically significant (P=0.1879, Fig. 7B). For microscopic lung lesions, both FV- and the 243 
two shuffled chimeric viruses-vaccinated groups had significantly lower scores than the 244 
non-vaccinated control group when challenged with NADC20 (Fig. 7C), but not with 245 
MN184B (Fig. 7D).  246 
For the pigs challenged with NADC20, both FV- and chimeric viruses-vaccinated groups 247 
had significantly decreased levels of serum viral RNA copies at 7 dpc compared to the 248 
non-vaccinated control group (Fig. 8A). The mean serum PRRSV viral RNA copy number of 249 
the FV-SPDS-VR2-vaccinated group (6.3×104 copies/ml) was numerically lower than that of 250 
the FV-vaccinated group (2.0×106 copies/ml), although the difference was not statistically 251 
significant (P=0.0841). Similarly, at 14 dpc (Fig. 8B), the mean serum viral RNA copies of 252 
the FV (1.3×105 copies/ml) and FV-SPDS-VR2 (5.0×104 copies/ml) vaccinated groups were 253 
significantly decreased when compared to the non-vaccinated control group (5.0×106 254 
copies/ml). Also, the viral RNA loads in the lung tissues of FV- and chimeric 255 
viruses-vaccinated groups at 14 dpc were significantly decreased when compared to the 256 
non-vaccinated control group (Fig. 8C). Three pigs in the FV-SPDS-VR2-vaccinated group 257 
and 1-3 pigs in the FV-vaccinated group were detected negative for viral RNA in serum 258 
samples or lung tissues (Fig. 8A-C).  259 
For the pigs challenged with MN184B, at 7 dpc, the serum viral RNA loads showed a 260 
significant decrease in groups vaccinated with FV (P=0.0311) or with FV-SPDS-VR2 261 
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(P=0.0297), but not with FV-SPDS-VR5 (P=0.1124), when compared to the non-vaccinated 262 
control group (Fig. 8D). Similarly, at 14 dpc (Fig. 8E), significant decreases in serum viral 263 
RNA loads were observed in FV-vaccinated pigs (P=0.0047), FV-SPDS-VR2-vaccinated 264 
pigs (P=0.0004), and FV-SPDS-VR5-vaccinated pigs (P=0.0125) compared to the control 265 
pigs. However, for the virus RNA loads in the lung at 14 dpc (Fig. 8F), neither FV- nor 266 
chimeric viruses-vaccinated groups had a statistically significant decrease compared to the 267 
control pigs. Also, the mean viral RNA load of the FV-SPDS-VR2-vaccinated group 268 
(6.3×108 copies/gram) was numerically lower than that of the FV-vaccinated group (1.6×1010 269 
copies/gram), although the difference was not statistically significant (P=0.1175).  270 
 271 
The chimeric FV-SPDS-VR2 and FV-SPDS-VR5 viruses were genetically stable in vivo 272 
  To investigate whether the multiple envelope genes-shuffled chimeric viruses 273 
FV-SPDS-VR2 and FV-SPDS-VR5 are genetically stable in vivo, the chimeric viruses were 274 
recovered from serum samples of infected pigs at 14 dpi. ORFs 2-6 were amplified by 275 
RT-PCR and sequenced. Sequence analyses revealed that the recovered viruses had 99.9% 276 
nucleotide sequence and 100% amino acids identity to the original virus inocula, indicating 277 
the genetic stability of the two shuffled viruses in pigs. 278 
 279 
Discussion 280 
Novel strategies for developing universal cross-protective vaccines have been explored for 281 
a number of antigenically highly-variable viruses such as influenza virus and HIV based on 282 
highly conserved antigens (Almeida et al., 2012; Neirynck et al., 1999; Pica and Palese, 283 
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2013). For PRRSV, which is also genetically and antigenically highly variable, thus far there 284 
is no vaccine that can provide sufficient cross-protection against all heterologous strains (Li 285 
et al., 2014; Martelli et al., 2009). Therefore, enhancing cross-protection is an important task 286 
but also the biggest challenge for the development of the next generation of PRRSV vaccines 287 
(Binjawadagi et al., 2014; Huang and Meng, 2010; Kimman et al., 2009). The heterogenic 288 
nature of the virus coupled with the fact that current vaccines are all based on a single virus 289 
strain explain why the current commercial vaccines are not fully effective in protecting 290 
against genetically diverse field strains of PRRSV. It is clear that heterogeneity needs to be 291 
considered when designing the next generation PRRSV vaccines, or PRRSV will remain 292 
difficult to control. 293 
Molecular breeding through DNA shuffling directs the evolution of a virus in vitro at an 294 
accelerated rate, thus making it a powerful tool to rapidly generate virus strains with desired 295 
properties (Crameri et al., 1998; Stemmer, 1994). For example, a chimeric dengue virus 296 
antigen produced by DNA shuffling induced tetravalent cross-neutralizing antibodies against 297 
four different serotypes of Dengue viruses (Apt et al., 2006). In our previous studies (Ni et al., 298 
2013; Zhou et al., 2013; Zhou et al., 2012), by using DNA shuffling, we successfully 299 
produced several single envelope gene shuffled chimeric PRRSV viruses in the genetic 300 
backbone of virulent strain VR2835. These shuffled viruses had an improved 301 
cross-neutralizing activity against heterologous PRRSV strains in vitro. Therefore, we reason 302 
that combining these single envelope gene-shuffled viruses with demonstrated 303 
cross-neutralizing activities into one “mosaic virus” may generate a candidate vaccine virus 304 
that will induce superior heterologous cross-protection than those single envelope 305 
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gene-shuffled viruses. Therefore, in this present study, by utilizing an infectious clone of the 306 
commercial vaccine Fostera® PRRS as the genomic backbone, we integrated the shuffled 307 
chimeric sequences from each of the single envelope gene-shuffled viruses (GP3TS22, 308 
GP4TS14, DS722, and MTS57) into one composite virus containing multiple shuffled 309 
envelope genes in various combinations. We successfully constructed and rescued five viable 310 
multiple envelope gene-shuffled chimeric viruses that could serve as potential vaccine 311 
candidates (Fig. 1). The growth kinetics and cross-neutralizing activities of the five chimeric 312 
viruses, and the heterologous cross-protective ability and vaccine efficacy of the two most 313 
promising chimeric viruses were investigated in this study.  314 
The five rescued chimeric viruses containing multiple shuffled envelope genes in different 315 
combinations (Fig. 1) replicated well in two cell lines, MARC-145 and ATCC CRL11171, 316 
suggesting that the gene shuffling did not significantly impair the growth of most of the 317 
resulting chimeric viruses. The shuffled chimeric viruses caused PRRSV-specific CPE and 318 
produced high virus yields (up to 106 TCID50/ml) in both MARC-145 and ATCC CRL11171 319 
cells, thus making these chimeric viruses viable candidates for further development into 320 
MLVs. 321 
Importantly, we demonstrated that these chimeric viruses induced robust immune 322 
responses in pigs as evidenced by the detection of high levels of anti-PRRSV N antibodies in 323 
infected pigs (Fig. 4). Most of the NA titers tested in this study were consistent with our 324 
previous studies, suggesting a good reproducibility of the SVN assay (Zhou et al., 2013; 325 
Zhou et al., 2012). Chimera FV-SPDS-VR5 induced significantly higher cross-neutralizing 326 
antibodies against heterologous strain VR2385, and chimera FV-SPDS-VR2 induced 327 
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significantly higher cross-neutralizing antibodies against NADC20. However, against the 328 
heterologous strains MN184B and FL12, the NA titers of the parental virus FV and all the 5 329 
chimeric viruses were very low (<1), and this was somewhat in contrast to our previous 330 
studies in which most NA titers were above 1 (Zhou et al., 2013; Zhou et al., 2012). We 331 
speculated that this was largely due to the fact that the virulent strain VR2385 backbone, 332 
which was used in our previous studies, can elicit higher levels of neutralizing antibodies 333 
against MN184B and FL12 than the vaccine virus FV backbone used in this present study. 334 
The data also suggested that the nonstructural proteins may also play roles in inducing NAs, 335 
and thus should be considered in the future vaccine design. In general, the NA titer against a 336 
particular virus strain was related to the sequence components of the shuffled envelope 337 
proteins. For example, compared to other shuffled viruses, FV-SPDS-FV5- and 338 
FV-SPDS-FV25-infected pigs developed higher NA titers against FV because the GP2 and/or 339 
GP5 of the FV-SPDS-FV5 and FV-SPDS-FV25 viruses were derived from FV (Fig. 1, 5A). 340 
FV-SPDS-VR2- and FV-SPDS-VR5-infected pigs had higher NA titers against VR2385 341 
because the GP2 or GP5 of the FV-SPDS-VR2 and FV-SPDS-VR5 viruses were derived 342 
from the VR2385 strain (Fig. 1, 5C), indicating that GP2 as well as GP5 are important in 343 
inducing neutralizing antibody, as GP2 is one of the viral attachment proteins interacting with 344 
cellular receptor CD163 (Das et al., 2010).  345 
Although the role of NAs in PRRSV protection is somewhat controversial, the NA titer is 346 
still an important criterion used by many research groups in evaluating candidate vaccine 347 
efficacy, especially for rapid screening of potential vaccine candidates for subsequent 348 
challenge-protection study (Binjawadagi et al., 2014; Wang et al., 2013). It is clear from the 349 
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composite NA titers against all heterologous strains tested in the study that FV-SPDS-VR2 350 
and FV-SPDS-VR5 induced significantly higher cross-neutralizing antibody titers than FV 351 
(Fig. 5F). Therefore, the FV-SPDS-VR2 and FV-SPDS-VR5 chimeric viruses were chosen 352 
for the subsequent cross-protective vaccine efficacy study in pigs. It is important to point out 353 
that the small pilot virus infection study in a small number of pigs (n=3) was meant to be an 354 
in vivo screening assay to identify a viable infectious virus that induces cross-neutralizing 355 
antibodies for the subsequent large vaccine challenge study in pigs. This pilot small pig study 356 
was simply to identify one chimeric virus that is infectious in pigs and induces 357 
cross-neutralizing antibodies.  358 
The body temperature, gross and histological pathology of the lungs, and the viral RNA 359 
loads in serum and lung tissues after challenge are the most commonly used parameters for 360 
assessing PRRSV vaccine efficacy (Kimman et al., 2009; Martelli et al., 2009; Wang et al., 361 
2013; Zuckermann et al., 2007). In general, more of the non-vaccinated/challenged pigs 362 
developed high body temperatures compared to the vaccinated/challenged pigs. For example, 363 
when challenged with NADC20 virus, only 1-2 pigs had a high body temperature in the FV- 364 
or chimeric viruses-vaccinated groups, while 7 pigs developed high body temperature in the 365 
unvaccinated/challenged control group (Fig. 6A). Importantly, both parental FV- and 366 
chimeric viruses-vaccinated groups showed significantly lower macroscopic and microscopic 367 
lung lesion scores (Fig. 7A, 7C) and lower viral RNA loads in sera and lung tissues (Fig. 368 
8A-C) than the control group. Also, the FV-SPDS-VR2-vaccinated group had numerically 369 
lower (but not significantly lower) viral RNA loads relative to the FV-vaccinated group. 370 
Together, this data suggest that the two shuffled chimeric viruses and the parental virus 371 
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provided good protection against heterologous PRRSV strain NADC20 challenge, and it can 372 
be hypothesized that the chimera FV-SPDS-VR2 may be well suited to control NADC20 373 
viremia by virtue of its NADC20 genetic components. 374 
We also included the highly virulent heterologous strain MN184B (lineage 1) as another 375 
challenge virus to measure the level of cross-protection, since no current commercial 376 
vaccines are based on lineage 1 viruses. When challenged with MN184B, 2 pigs in the 377 
FV-SPDS-VR2-vaccinated group and 3 pigs in the FV-SPDS-VR5-vaccinated group had 378 
high body temperature, while 6 pigs in FV-vaccinated group and 4 pigs in the control group 379 
developed high body temperatures (Fig. 6B), indicating that the candidate chimeric virus 380 
vaccines can reduce fever associated with PRRSV infection. FV- and 381 
FV-SPDS-VR2-vaccinated groups also showed significantly lower levels of macroscopic 382 
lung lesion scores (Fig. 7B) and serum viral RNA loads (Fig. 8D, 8E) compared to the 383 
control group. Also, the FV-SPDS-VR2-vaccinated group had low macroscopic lung lesion 384 
scores (Fig. 7B) and low viral RNA loads in lungs (Fig. 8F). Taken together, the data suggest 385 
that chimera FV-SPDS-VR2, and parental FV provided partial cross-protection against the 386 
highly-virulent heterologous strain MN184B. It was noted that neither parental FV nor 387 
chimera FV-SPDS-VR2 induced a high level of NA titers based on SVN assay (Fig. 5E). 388 
Therefore, cellular immune cytokines such as interferon-gamma might also be involved in the 389 
protection. Unfortunately, no significant level of interferon gamma was detectable in sera at 0 390 
dpc and 14 dpc, and the lack of fresh PBMCs (not collected in this study) prevented us from 391 
performing further cytokine testings in this study. 392 
In summary, in this study we successfully generated five multiple envelope genes-shuffled 393 
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chimeric viruses in the genomic backbone of a commercial PRRSV vaccine virus FV. The 394 
rescued chimeric viruses replicated well in two cell lines and produced robust immune 395 
responses in pigs. One shuffled chimeric virus, FV-SPDS-VR2, and its parental FV induced 396 
partial cross-protection when challenged with two heterologous strains NADC20 and 397 
MN184B. We demonstrated in this study that simultaneous multiple envelope gene-shuffling 398 
of PRRSV is a viable approach to generate potential vaccine candidates that possess 399 
cross-protective ability and may lead to novel vaccines with enhanced cross-protection 400 
against diverse PRRSV strains. 401 
 402 
Materials and methods 403 
Cells and viruses  404 
BHK-21 cells were cultured in Dulbecco’s Minimal Essential Medium (DMEM) 405 
supplemented with 10% fetal bovine serum (FBS). Two different clones of monkey kidney 406 
cell line MA104, MARC-145 and ATCC CRL11171 (Halbur et al., 1995; Kim et al., 1993; 407 
Meng et al., 1996), were cultured in low glucose-supplemented DMEM with 10% FBS, and 408 
maintained in low glucose DMEM with 2% FBS for virus propagation. The cells were 409 
cultured in an incubator at 37°C with 5% CO2. An infectious cDNA clone of the commercial 410 
vaccine virus Fostera® PRRS in a DNA-launched plasmid format (pFV) was chemically 411 
synthesized based on the complete genome sequence of the vaccine virus. As a positive 412 
control, Fostera-like virus (FV) was generated by direct transfection of cells with pFV, and 413 
evaluated in parallel with gene-shuffled chimeric viruses. Fostera® PRRS is derived from 414 
strain P129 (Accession no. AF494042), which is a lineage 8 PRRSV based on its ORF5 415 
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sequence. PRRSV strains from distinct genetic lineages of genotype 2 including VR2430 416 
(lineage 5, accession no. JX050225), VR2385 (lineage 5, accession no. JX044140), NADC20 417 
(lineage 9, accession no. JX069953), MN184B (lineage 1, accession no. DQ176020), and 418 
FL12 (lineage 8, accession no. AY545985) were propagated, titrated and stored at -80°C 419 
before use (Ni et al., 2013; Shi et al., 2010b).  420 
 421 
Construction of chimeric virus clones containing shuffled multiple envelope genes  422 
In our previous studies, based on the genomic backbone of the PRRSV strain VR2385, we 423 
generated several single envelope gene-shuffled chimeric viruses that possess in vitro 424 
cross-neutralizing activities against heterologous PRRSV strains or in vivo attenuated 425 
pathogenicity: GP3TS22 (shuffled ORF3), GP4TS14 (shuffled ORF4), DS722 (shuffled 426 
ORF5), and MTS57 (shuffled ORF6). In order to design a vaccine with maximal 427 
cross-protection against heterologous strains, we incorporated, in different combinations, the 428 
shuffled multiple envelope genes into the genomic backbone of the vaccine virus infectious 429 
clone pFV. Briefly, based on the envelope gene sequences of the four single gene-shuffled 430 
chimeric viruses (GP3TS22, GP4TS14, DS722, and MTS57) and the predicted structural 431 
topology of the PRRSV envelope proteins (Dokland, 2010), we designed and synthesized a 432 
nucleotide sequence fragment, designated SPDS, which contains the ORFs 2 through 6. For 433 
the SPDS sequence, the GP2 ectodomain-encoding region was derived from strain MN184B, 434 
GP3 from chimera GP3TS22, GP4 from chimera GP4TS14, and GP5 from chimera DS722. 435 
The entire M sequence was derived from chimera MTS57. The non-ectodomain regions of 436 
GP2 through 5 were from pFV. The overlapping sequences of ORFs 2-3 were derived from 437 
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chimera GP3TS22, and the overlapping sequences of ORFs 3-4 were from chimera GP4TS14. 438 
The genomic organizations of the chimeric virus constructs are depicted in Fig. 1.  439 
By using the Afe I and Spe I restriction enzyme sites engineered in the synthesized 440 
fragment SPDS, the ORFs 2-6 were introduced into the genomic backbone of pFV, to 441 
generate the chimeric virus designated FV-SPDS. Subsequently, based on the chimeric clone 442 
FV-SPDS, we constructed four other chimeric virus clones: FV-SPDS-FV5 (ORF5 derived 443 
from FV), FV-SPDS-FV25 (ORF2 and ORF5 from FV), FV-SPDS-VR2 (ORF2 from 444 
VR2385), and FV-SPDS-VR5 (ORF5 from VR2385) through fusion PCR as described 445 
elsewhere (Ni et al., 2013; Tian et al., 2012). Briefly, two flanking fragments amplified from 446 
pFV were fused to the corresponding target ORFs to form hybrid fragments. By utilizing the 447 
restriction enzyme sites in the flanking fragments, the hybrid fragments were then cloned into 448 
the pFV backbone to generate the four chimeric virus clones (Fig. 1). All the chimeric virus 449 
constructs were verified by nucleotide sequencing. 450 
 451 
In vitro transfection to rescue chimeric viruses 452 
Plasmid DNAs from full-length DNA-launched chimeric virus infectious clones were 453 
isolated using the QIAprep Spin Miniprep kit, and quantified using Nanodrop. Fresh BHK-21 454 
cells in a 6-well plate at approximately 60–80% confluency were transfected with 2 µg of 455 
plasmid DNA per well using Lipofectamine LTX and Plus Reagent kit (Invitrogen) according 456 
to the manufacturer’s instructions, followed by incubation at 37°C with 5% CO2. At 48 h 457 
post-transfection, cell culture supernatants were harvested and designated as passage 0 (P0) 458 
viruses.  459 
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 460 
Indirect immunofluorescence assay (IFA)  461 
At 48 h post-inoculation, cells were washed twice with phosphate-buffered saline (PBS) 462 
and fixed in cold methanol for 15 min. After washing with PBS, the fixed cells were blocked 463 
in 1% bovine serum albumin (BSA) at room temperature for 30 min, washed with PBS and 464 
then incubated with anti-PRRSV N monoclonal antibody SDOW17 (Rural Technologies, Inc.) 465 
at 37°C for 2 h. After extensive washing with PBS, the cells were incubated with fluorescein 466 
isothiocyanate (FITC) or Alexa Fluor 594-conjugated goat anti-mouse IgG for 1 h at 37°C. 467 
After washing with PBS, fluorescent signals were visualized using an Olympus inverted 468 
fluorescence microscope fitted with a digital camera. 469 
 470 
Virus growth kinetics assay 471 
To investigate the growth properties of the shuffled chimeric viruses in MARC-145 and 472 
ATCC CRL11171 cells, a multiple-step growth curve analysis was conducted. Briefly, 473 
MARC-145 or ATCC CRL11171 cells in 6-well plates were infected with each of the 474 
shuffled chimeric viruses as well as parental FV virus (passage P3) at a low multiplicity of 475 
infection (MOI) of 0.1. At 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 h post-infection (hpi), 476 
200 µl of each cell culture supernatant was collected, and wells were replenished with the 477 
same volume of fresh culture medium. Virus titrations were performed in MARC-145 or 478 
ATCC CRL11171 cells in 96-well plates with fresh cells that were inoculated with 10-fold 479 
serial virus dilutions (4 replicates per dilution, 100 µl/well) for 1 h, after which the cells were 480 
washed with PBS and then incubated in low glucose DMEM with 2% FBS in a humidified 481 
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CO2 incubator. Presence of a cytopathic effect (CPE) was determined at 7 days 482 
post-inoculation. Viral titers were calculated using the Reed-Muench method and expressed 483 
as the 50% tissue culture infectious dose per milliliter (TCID50/ml). Three independent 484 
experiments were carried out for each virus.  485 
 486 
Experimental design for a small pilot chimeric virus infection study in pigs to generate 487 
antibodies against each of the five chimeric viruses   488 
In order to screen for potential candidate viable chimeric virus strains for the subsequent 489 
vaccine efficacy testing, and to determine the viability of the multiple envelope gene-shuffled 490 
chimeric viruses in pigs, we conducted a small pilot in vivo pig infection study with the 5 491 
chimeric viruses (FV-SPDS, FV-SPDS-FV5, FV-SPDS-FV25, FV-SPDS-VR2, and 492 
FV-SPDS-VR5). A total of 21 pigs were divided into 7 groups of 3 pigs each, and each group 493 
was inoculated with one of the 5 chimeras. Weekly serum samples were collected from each 494 
pig for a total of 7 weeks. The sera were tested for PRRSV neutralizing antibodies against 495 
homologous and heterologous strains as well as PRRSV antibody responses using the IDEXX 496 
HerdChek® X3 ELISA kit according to the protocol provided by the manufacturer. All 497 
experiments involving animals were conducted in compliance with national legislation and 498 
subject to review by both Virginia Tech and Iowa State University Institutional Animal Care 499 
and Use Committee (IACUC).  500 
 501 
Serum virus neutralization assay to evaluate cross-neutralizing activities 502 
The neutralizing antibody (NA) titers against homologous and heterologous PRRSV strains 503 
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were determined by a serum virus neutralization (SVN) assay essentially as previously 504 
described (Zhou et al., 2012). Briefly, 2-fold diluted serum samples collected at 49 days 505 
post-inoculation (dpi) from each pig were mixed with an equal volume of individual 506 
homologous (FV) or heterologous (VR2430, VR2385, NADC20, MN184B and FL12) virus 507 
at an infectious titer of 2×103 TCID50/ml and incubated at 37°C for 1 h. The mixtures were 508 
then dispensed onto ATCC CRL11171 cells in 96-well plates and incubated for 1 h at 37°C. 509 
After washing with PBS, the cells were maintained in DMEM with 2% FBS. At 510 
approximately 20 hpi, the cells were assayed by IFA for virus infection. The NA titers were 511 
expressed as the highest dilution that showed at least 90% reduction in the number of 512 
fluorescent foci compared to antisera from negative control pigs. Three independent tests 513 
were performed for each serum sample. 514 
 515 
Experimental design for a vaccine efficacy and cross-protection study in pigs  516 
Based on the cross-neutralizing activities of the sera from pigs infected with each of the 5 517 
chimeric viruses, we selected two chimeric viruses (FV-SPDS-VR2 and FV-SPDS-VR5) for 518 
a vaccine efficacy study in pigs. Briefly, a total of 72 PRRSV-negative piglets at 3 weeks of 519 
age were divided into 9 groups of 8 piglets per group. Piglets in each group were vaccinated 520 
with one of the two shuffled chimeric viruses (FV-SPDS-VR2, or FV-SPDS-VR5), parental 521 
virus (FV) derived from the pFV infectious clone, or PBS as shown in Table 1. Serum 522 
samples were collected from each pig prior to vaccination and weekly thereafter. At 42 days 523 
post-vaccination, the pigs were challenged with two heterologous virus strains NADC20 or 524 
MN184B as shown in Table 1. At 14 days post-challenge (dpc), all pigs were necropsied for 525 
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gross pathological and histopathological lesion evaluation. Serum samples at 7 dpc and 14 526 
dpc as well as the samples of lung tissues at 14 dpc were used to quantify PRRSV viral RNA 527 
loads. The body temperatures from all pigs were also monitored every 2 days after challenge. 528 
 529 
Quantitation of viral RNA loads in sera and lung tissues 530 
 Viral RNAs were extracted from serum samples at 7 and 14 dpc using ZR Viral RNA kit 531 
(ZYMO RESEARCH, USA) according to the protocol provided by the manufacturer. Total 532 
RNAs from samples of lung tissues were extracted using TRI Reagent (MRC). The RNA 533 
standard used for the RT-qPCR was derived from in vitro transcription of a PRRSV 534 
full-length cDNA clone pACYC-VR2385 by mMESSAGE mMACHINE T7 kit (Ambion). 535 
The PRRSV RNA copy numbers in sera or lung tissues were quantified by a SYBR 536 
green-based quantitative PCR using SuperScript III Platinum SYBR Green One-Step 537 
RT-qPCR kit (Invitrogen) with a protocol recommended by the manufacturer. The primer set 538 
(realtime2F/2R, binds to the conserve region of ORF7) used in the RT-qPCR assay was 539 
previously validated elsewhere (Ni et al., 2013; Ni et al., 2014). The RT-qPCR assay was 540 
conducted in a CFX96 real-time (RT) PCR system (Bio-Rad). Each reaction was performed 541 
in triplicate.  542 
 543 
Gross pathology and histopathology evaluation  544 
All pigs were humanely euthanized by intravenously overdose injection of pentobarbital 545 
(Fatal-Plus, Vortech Pharmaceutical Ltd., Dearborn, MI). At necropsy, the lungs were 546 
evaluated for gross pathology, and subsequently five sections of lung tissues were collected, 547 
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fixed in 10% neutral-buffered formalin and processed for histopathology evaluation. Fresh 548 
lung tissues were also collected and stored at -80°C for quantification of viral RNA loads by 549 
RT-qPCR.  550 
The criteria for evaluating the gross pathology and histopathology have been well 551 
established and described previously (Halbur et al., 1995; Ni et al., 2013). For gross 552 
pathology evaluation, the total amount of lung lesions affected by pneumonia of each pig 553 
(0-100% of the lung affected by visible pneumonia) was scored by a veterinary pathologist 554 
(PGH) who was blinded to the treatment status of pigs. The scoring system is based on the 555 
approximate volume that each lung lobe contributes to the entire lung: the right cranial lobe 556 
(10%), right middle lobe (10%), cranial part of the left cranial lobe (10%), caudal part of the 557 
left cranial lobe (10%), the accessory lobe (5%), and right and left caudal lobes (27.5% each). 558 
The microscopic lung lesions were evaluated and scored independently by two veterinary 559 
pathologists (TO and PGH) who were blinded to the treatment status. The scores based on the 560 
presence and severity of interstitial pneumonia ranging from 0 to 6 (0, normal; 1, mild 561 
multifocal; 2, mild diffuse; 3, moderate multifocal; 4, moderate diffuse; 5, severe multifocal; 562 
6, severe diffuse). The mean of the two scores obtained for each pig was used as the final 563 
value. 564 
 565 
Statistical analyses 566 
The Student’s t test (unpaired) was used to evaluate the differences (P<0.05) between the 567 
samples in the two groups. The data were analyzed using GraphPad Prism (version 5.0). 568 
 569 
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Table 1. Experimental design for the cross-protective vaccine efficacy study in pigs 720 
Group No. of 
pigs 
Vaccination at 0 dpi 
(1.0×104.0 TCID50/pig) 
with 
Challenge at 42 dpi 
(1.0×105.0 TCID50/pig) 
with 
No. of pigs at 
necropsy (14dpc) 
1 8 FV-SPDS-VR2 NADC20 8 
2 8 FV-SPDS-VR2 MN184B 7a 
3 8 FV-SPDSVR5 NADC20 8 
4 8 FV-SPDSVR5 MN184B 8 
5 8 FV NADC20 8 
6 8 FV MN184B 8 
7 8 PBS NADC20 8 
8 8 PBS MN184B 8 
9 8 PBS PBS 8 
a One piglet died from an unrelated cause before challenge. 721 
722 
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Figure captions 723 
FIG. 1. Schematic diagrams of the organization of multiple envelope genes of backbone 724 
FV virus and 5 shuffled chimeric PRRSVs.  The genes derived from the backbone FV 725 
virus are depicted with open rectangles. The predicted ectodomains of the envelope genes are 726 
represented by gray bars with numbers showing the start and ending nucleotide positions. 727 
Each pattern in the shuffled genes represents one of the six individual heterologous donor 728 
parental virus strains, which are shown at the bottom. 729 
 730 
FIG. 2. Successful rescue and replication of multiple envelope gene-shuffled chimeric 731 
viruses. Two days post-transfection of BHK-21 cells with the vaccine virus FV backbone and 732 
shuffled chimeric virus clones, the P0 virus supernatants were harvested and used to inoculate 733 
fresh MARC-145 (A) or ATCC CRL11171 (B). MARC-145 or ATCC CRL11171 cells were 734 
fixed at 48 h post-inoculation, and immunostained by IFA with anti-PRRSV N monoclonal 735 
antibody (SDOW17). 736 
 737 
FIG. 3. Growth kinetics and characteristics of multiple envelope gene-shuffled chimeric 738 
viruses in MARC-145 and ATCC CRL11171 cells. The parental FV and the rescued 739 
shuffled chimeric viruses were passaged in MARC-145 or ATCC CRL11171 cells to P3, and 740 
the P3 virus was then used to infect fresh MARC-145 (A) or ATCC CRL11171 (B) cells at 741 
an MOI of 0.1. The culture supernatants were collected at indicated time points. Infectious 742 
viral titers were determined and calculated using the Reed-Muench method. Three 743 
independent experiments were carried out for each virus. The open symbols were used to 744 
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represent the chimeric viruses that were not selected for the subsequent challenge study. (C) 745 
Peak virus titers in MARC-145 and ATCC CRL11171 cells. 746 
 747 
FIG. 4. Kinetics of anti-PRRSV antibody response in pigs experimentally infected with 748 
each of the five shuffled chimeric viruses as well as the parental virus FV. The 749 
anti-PRRSV N antibody titers at indicated time points were detected using the IDEXX 750 
HerdChek® X3 ELISA kit. The level of antibody was expressed as a sample/positive (S/P) 751 
value ratio. The dash line shows the cutoff threshold (S/P value ≥0.4). Each plot represents 752 
the mean value of 3 pigs in one group at that time point. 753 
 754 
FIG. 5. Neutralizing antibody (NA) titers induced by each of the five chimeric viruses in 755 
pigs against homologous and heterologous PRRSV strains. At 49 dpi, the sera from pigs 756 
experimentally infected with FV and the 5 chimeric viruses were collected to determine the 757 
NA titers using ATCC CRL11171 cells by SVN assay. The NA titers against parental strain 758 
FV (A), and heterologous strains VR2430 (B), VR2385 (C), NADC20 (D), and MN184B (E) 759 
were expressed as the highest dilution (2n) that showed a 90% or above reduction in the 760 
number of fluorescent foci compared to that of serum from negative control group. The NA 761 
titers against FL12 were not shown because most samples had undetectable NA titers. (F) 762 
The composite NA titers against five heterologous virus strains (VR2430, VR2385, NADC20, 763 
MN184B, FL12). The composite titers were generated by combining the individual NA titers 764 
against five respective heterologous PRRSV strains. Three independent experiments were 765 
performed for each test, and the error bars indicate standard errors. The P values are shown if 766 
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one shuffled virus group displayed significant higher NA titers than that of parental FV group 767 
(* P<0.05, ** P<0.01, *** P<0.001). 768 
 769 
FIG. 6. Kinetics of body temperature of pigs in the vaccine efficacy and challenge study. 770 
Pig body temperatures were measured every 2 days after challenge with NADC20 (A) or 771 
MN184B (B). The numbers in brackets represent the number of pigs which developed a body 772 
temperature above 104.5°F after challenge. 773 
 774 
FIG. 7. Macroscopic and microscopic lung lesion scores at 14 dpc. At necropsy, the lung 775 
tissues were scored for macroscopic lesions by a veterinary pathologist (A, B). The lung 776 
tissues were also fixed in neutral formalin for histological examination of microscopic lung 777 
lesion scores by two independent veterinary pathologists and the mean of two scores were 778 
used as the final value (C, D). Each plot represents the value of one pig, and the error bars 779 
indicate standard errors. Significant differences are indicated with asterisks (* P<0.05, ** 780 
P<0.01, *** P<0.001). 781 
 782 
FIG. 8. Viral RNA loads in sera and lung tissues after challenge with two heterologous 783 
strains. The PRRSV RNA copy numbers in sera at 7 dpc (A, D) and 14 dpc (B, E), and in 784 
lung tissues at 14 dpc (C, F) were determined using quantitative RT-PCR. The detection limit 785 
is 1000 (3 log10) RNA copies per ml or gram. The samples under detection limit were 786 
considered as negative, and calculated as 2 log10 copy number. Each sample was tested in 787 
three separate reactions. Each plot represents the mean viral RNA copy number of three 788 
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separate tests of one pig, and the error bars indicate standard errors. Significant differences 789 
are indicated with asterisks (* P<0.05, ** P<0.01, *** P<0.001). 790 
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